Regresar

ADVERSE EFFECTS OF IVERMECTIN IN SARS-COV-2 PATIENTS

Abstract:

Through a literature review in high impact journals, it was determined that ivermectin, besides being a drug widely recogni-zed for its ability to treat and control parasitic infections, has several relevant clinical actions, such as the possibility of era¬dicating onchocerciasis or “river blindness”, considering this fact as a triumph of humanity by the WHO in 2009. The broad-spectrum antiviral potential of this drug against a variety of RNA viruses is raised, due to its ability to specifically inhibit nuclear transport mediated by α/β importin, capable of blocking nuclear trafficking of viral proteins. The proposed anti-SARS-CoV-2 action of ivermectin involves its binding to the IMPα/β1 heterodimer that will bind to the coronavirus cargo protein causing the viral load to reduce the antiviral response of the host cell, improving the clinical conditions of the patient. Several clinical trials of the use of ivermectin in relation to COVID-19 have shown that this drug could produce a slight improvement in its symptomatology, so this literature review aims to determine the pharmacokinetics and adverse effects of ivermectin, as a possible treatment of SARS-CoV-2.